Saturday, 5 September 2026European Markets

MYHOTELMATCH Stock Bearish Momentum With A 30% Fall In The Last 21 Sessions

Loading stream...

(vianews) - shares of myhotelmatch (cac 40: mhm.pa) dropped by a staggering 30.07% in 21 sessions from €0.03 to €0.02 at 08:05 est on tuesday, after two consecutive sessions in a row of losses. cac 40 is sliding 0.18% to €7,386.70, after five consecutive sessions in a row of gains.

myhotelmatch's last close was €0.02, 56.19% under its 52-week high of €0.04.

about myhotelmatch

myhotelmatch s.a. engages in the development and exploitation of an online hotel reservation platform based on artificial intelligence (ai). it operates as an online travel agency based on the principle of online dating. the company, through its platform, connect a traveler and hotels with online hotel services whose profiles match. the company is based in biot, france.

earnings per share

as for profitability, myhotelmatch has a trailing twelve months eps of €-0.04.

volume

today's last reported volume for myhotelmatch is 3483231 which is 21.76% below its average volume of 3308360.

moving average

myhotelmatch's worth is way under its 50-day moving average of €0.03 and below its 200-day moving average of €0.02.

more news about myhotelmatch (mhm.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com